Formulation Study for Lansoprazole Fast-disintegrating Tablet. : III. Design of Rapidly Disintegrating Tablets
スポンサーリンク
概要
- 論文の詳細を見る
Lansoprazole fast-disintegrating tablets (LFDT) are a patient-friendly formulation that rapidly disintegrates in the mouth. LFDT consist of enteric-coated microgranules (mean particle size, approximately 300μm) and inactive granules. In the design of the inactive granules, mannitol was used as a basic excipient. Microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), and crospovidone were used as binders and disintegrants. A new grade of L-HPC (L-HPC-33), with a hydroxypropoxy group content of 5.0-6.9%, was developed and it has no rough texture due to a decrease in water absorption. It was clarified that L-HPC-33 could be useful as a binder and disintegrant in rapidly disintegrating tablets. LFDT contain enteric-coated microgranules in tablet form. The enteric-coated microgranule content in LFDT affect qualities such as tensile strength, disintegration time in the mouth, and dissolution behavior in the acid stage and in the buffer stage of LFDT. The 47.4% content of the enteric-coated microgranules was selected to give sufficient tensile strength (not less than 30 N/cm^2), rapid disintegration time in the mouth (not more than 30s), and dissolution behavior in the acid stage and buffer stage similar to current lansoprazole capsules. Compression force affected the tensile strength and the disintegration time in the mouth, but did not affect the dissolution behavior in the acid and buffer stages.
- 公益社団法人日本薬学会の論文
- 2003-10-01
著者
-
Hamaguchi N
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Nakano Yoshinori
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Shimizu Toshihiro
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
SUGAYA Masae
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
IZUTSU Daisuke
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
MIZUKAMI Yoshio
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
OKOCHI Kazuhiro
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
TABATA Tetsuro
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
HAMAGUCHI Naoru
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
IGARI Yasutaka
Pharmaceutical Development Laboratories, Pharmaceutical Production Division, Takeda Chemical Industr
-
Sugaya Masae
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Tabata T
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Igari Yasutaka
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Izutsu Daisuke
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Okochi Kazuhiro
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
-
Mizukami Y
Pharmaceutical Development Laboratories Pharmaceutical Production Division Takeda Chemical Industrie
関連論文
- Purification and Characterization of a Novel Glycoprotein Which Has Significant Homology to Heavy Chains of Inter-α-Trypsin Inhibitor Family from Human Plasma
- Regulation of Gelatin-Binding Protein 28 (GBP28) Gene Expression by C/EBP
- Cloning of the cDNA for a Mouse Homologue of Human PHBP : a Novel Hyaluronan-Binding Protein
- Isolation and Characterization of GBP28, a Novel Gelatin-Binding Protein Purified from Human Plasma
- Molecular Cloning and Expression of Human Liver Biliverdin-IXβ Reductase
- Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Growth Factor Activator
- Isolation and Characterization of the Human Inter-α-Trypsin Inhibitor Family Heavy Chain-Related Protein (IHRP) Gene (ITIHL1)
- Aryl-Aryl Coupling Reaction Using a Novel and Highly Active Palladium Reagent Prepared from Pd(OAc)_2, 1,3-Bis [diphenylphosphino] propane (DPPP), and Bu_3P
- Synthesis of a New Dual Metalloprotease Inhibitor. II. Stereoselective Synthesis of Peptidomimetic [5.7]-Bicyclic Compounds
- Synthesis of a New Dual Metalloprotease Inhibitor. I. Diastereoselective Alkylation of Protected 6-Oxopipecolic Acid Esters
- Cloning and Characterization of cDNA for Inter-α-Trypsin Inhibitor Family Heavy Chain-Related Protein (IHRP), a Novel Human Plasma Glycoprotein
- Formulation Study for Lansoprazole Fast-disintegrating Tablet. : III. Design of Rapidly Disintegrating Tablets
- Formulation Study for Lansoprazole Fast-disintegrating Tablet. I. Effect of Compression on Dissolution Behavior
- INTERNAL ARYL-ARYL COUPLING REACTION USING A NOVEL AND HIGHLY ACTIVE PALLADIUM REAGENT PREPARED FROM Pd(OAc)_2,DPPP, and Bu_3P
- Formulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products